Zalutumumab

Drug Profile

Zalutumumab

Alternative Names: HuMax-EGFr

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genmab
  • Developer Danish Head and Neck Cancer Group; Genmab
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Dimerisation inhibitors; Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Head and neck cancer
  • Discontinued Colorectal cancer; Non-small cell lung cancer

Most Recent Events

  • 22 Sep 2011 Genmab completes a phase III trial in Head and Neck cancer in Brazil, Canada, Russia, and EU (NCT00382031)
  • 24 Jun 2011 Suspended - Phase-II for Head and neck cancer in USA (IV)
  • 24 Jun 2011 Suspended - Phase-III for Head and neck cancer in Belgium (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top